Alzheimer’s disease (AD) is responsible for 60–70% of all cases of dementia. On the other hand, the tap water consumed by hundreds of millions of people has been fluoridated to prevent tooth decay. However, little is known about the influence of fluoride on the expression of APP and subsequent changes in learning and memory and neuropathological injury. Our aim here was to determine whether exposure to fluoride aggravates the neuropathological lesions in mice carrying the amyloid precursor protein (APP)/presenilin1 (PS1) double mutation. These transgenic or wide-type (WT) mice received 0.3 ml of a solution of fluoride (0.1 or 1 mg/ml, prepared with NaF) by intragastric administration once each day for 12 weeks. The learning and memory of these animals were assessed with the Morris water maze test. Senile plaques, ionized calcium binding adaptor molecule 1 (Iba-1), and complement component 3 (C3) expression were semi-quantified by immunohistochemical staining; the level of Aβ42 was detected by Aβ42 enzyme-linked immunosorbent assays (ELISAs); the levels of synaptic proteins and enzymes that cleave APP determined by Western blotting; and the malondialdehyde (MDA) content and activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) measured by biochemical procedures. The untreated APP mice exhibited a decline in learning and memory after 12 weeks of fluoride treatment, whereas treatment of these some animals with low or high levels of fluoride led to such declines after only 4 or 8 weeks, respectively. Exposure of APP mice to fluoride elevated the number of senile plaques and level of Aβ42, Iba-1, and BACE1, while reducing the level of ADAM10 in their brains. The lower levels of synaptic proteins and enhanced oxidative stress detected in the hippocampus of APP mice were aggravated to fluoride. These findings indicate that exposure to fluoride, even at lower concentration, can aggravate the deficit in learning and memory and neuropathological lesions of the mice that express the high level of APP.
In patients with advanced high-grade serous ovarian carcinoma (HGSOC), the standard treatment typically involves platinum-based chemotherapy after debulking surgery. However, the prognosis of patients following platinum-based chemotherapy varies, and known prognostic factors do not fully explain this variability. Therefore, developing an accurate and validated prognostic tool is essential. This study retrospectively analyzed hematoxylin and eosin (H&E) staining whole-slide images (WSIs) from 392 advanced HGSOC patients. A pathomics signature (PS) was developed and validated using pathomics features derived from the best model in an integrated machine learning framework. Discrimination performance was quantified using time-dependent 5-year receiver operating characteristic (ROC) curves. Calibration curves were also generated to compare predicted survival probabilities with actual outcomes. Genomic analysis was performed to elucidate the molecular mechanisms underlying the model's predictions. PS demonstrated significant risk stratification for overall survival and successfully identified patients likely to benefit from platinum-based chemotherapy. The predictive power of PS was validated in an external validation cohort. Furthermore, genomic analysis suggested that PS is influenced by the cytoskeleton, protein digestion and absorption pathways, and is correlated with immune cell infiltration, which may help predict the prognosis of advanced HGSOC patients after platinum-based chemotherapy. PS based on pathomics features is a potential prognostic marker for advanced HGSOC patients after platinum-based chemotherapy. This marker demonstrates robust prognostic ability and broad applicability. Further prospective studies are needed to assess the practical application of this model in precision therapy.